Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moderna (MRNA) a catalyst driven idea at Morgan Stanley
January 6, 2023 12:17 PM ESTMorgan Stanley analyst Matthew Harrison labeled Moderna (NASDAQ: MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock.
The analyst told investors the firm expects Moderna's first interim analysis from its Ph3 RSV vaccine study in the near term.
"We believe efficacy and... More
CytomX Therapeutics (CTMX) Climbs 50% Following Pact with Moderna on Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 5, 2023 4:37 PM ESTCytomX Therapeutics (NASDAQ: CTMX) Climbs 50% Following Pact with Moderna on Collaboration for mRNA-Based Conditionally Activated Therapeutics
... MoreMorgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More
